Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
Jun 1, 2025 · The combination of anti–programmed death ligand 1 (PD-L1) therapy and chemotherapy has shown encouraging outcomes and is approved for the treatment of …
AstraZeneca wins landmark approval for IMFINZI regimen in early …
WILMINGTON, DE — AstraZeneca secured U.S. approval for its IMFINZI (durvalumab) regimen in combination with FLOT chemotherapy for early-stage and locally advanced gastric and …
What is the FLOT chemotherapy regimen and how does it work?
Aug 12, 2025 · This regimen is now considered a standard of care for patients with resectable gastric, gastroesophageal junction, and esophageal adenocarcinoma, based on clinical trial …
The efficacy and safety of PD-1/PD-L1 inhibitors in combination …
Mar 26, 2025 · The efficacy and safety of PD-1/PD-L1 inhibitors in combination with chemotherapy as a first-line treatment for unresectable, locally advanced, HER2-negative …
Imfinzi-based regimen demonstrated statistically significant and ...
Mar 7, 2025 · The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and …
The efficacy and safety of PD-1/PD-L1 inhibitors in combination …
Mar 26, 2025 · Abstract Background: Immune checkpoint inhibitors (ICIs) plus fluorouracil-based chemotherapy (Chemo) have been approved as an initial treatment strategy for metastatic or …
First-line cadonilimab plus chemotherapy in HER2-negative
Jan 22, 2025 · Programmed cell death protein-1 (PD-1) inhibitors plus chemotherapy have been the standard of care in the first-line treatment of advanced gastric or gastroesophageal …
FDA approves durvalumab for resectable gastric or gastroesophageal
Nov 25, 2025 · The recommended durvalumab dose for patients with a body weight of ≥30 kg is 1,500 mg every 4 weeks with chemotherapy for up to 4 cycles (neoadjuvant and adjuvant …
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and ...
Dec 27, 2024 · Gastric Cancer In combination with platinum and fluoropyrimidine-based chemotherapy for the treatment of adult patients with unresectable or metastatic HER2 …
Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy …
6 days ago · HONG KONG, Dec. 9, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that data from the Phase II study (COMPASSION-25) for its first-in …